EUCTR2018-000504-42-ES进行中（未招募）1 期
A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease - ABO-102 for Treatment of Middle and Advanced Phases of MPS IIIA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of MPS IIIA confirmed by the following methods:
- •o No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and
- •o Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene
- •Cognitive Development Quotient (DQ) lower than 60 (calculated by Bayley Scales of Infant and Toddler Development - Third Edition)
- •Must be ambulatory, though may receive assistance with ambulation
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Inability to participate in the clinical evaluation as determined by Principal Investigator
- •Identification of two nonsense or null variants on genetic testing of the SGSH gene
- •At least one S298P mutation in the SGSH gene
- •Has evidence of an attenuated phenotype of MPS IIIA
- •Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
- •Active viral infection based on clinical observations
- •Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer, or precludes the child from participating in the protocol assessments and follow up
- •Participants with total anti-AAV9 antibody titers = 1:100 as determined by ELISA binding immunoassay
- •Participants with a positive response for the ELISPOT for T-cell responses to AAV9
- •Serology consistent with exposure to HIV, or serology consistent with active hepatitis B or C infection
- •Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy
- •Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing
- •Any item (braces, etc.) which would exclude the participant from being able to undergo MRI according to local institutional policy
- •Any other situation that precludes the participant from undergoing procedures required in this study
- •Participants with cardiomyopathy or significant congenital heart abnormalities
- •The presence of significant non-MPS IIIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
- •Abnormal laboratory values Grade 2 or higher as defined in CTCAE v4.0 for GGT, total bilirubin (except in subjects diagnosed with Gilbert’s syndrome), creatinine, hemoglobin, WBC count, platelet count, PT and aPTT
- •Female participant who is pregnant or demonstrates a positive urine or beta-hCG result at screening assessment (if applicable)
- •Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)
- •Previous treatment by Haematopoietic Stem Cell transplantation
- •Previous participation in a gene/cell therapy or ERT clinical trial
- •Participants who are anticipated to undergo a procedure involving anesthesia within 6 months post- drug administration
- •Dysphagia present at Grade 3 or higher, as defined in CTCAE v4.0
研究者
相似试验
撤回
3 期
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous InfusioNL-OMON48542AveXis5
进行中（未招募）
1 期
Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophyMedDRA version: 20.1Level: PTClassification code 10052655Term: Duchenne muscular dystrophy gene carrierSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2022-000691-19-FRF. Hoffmann-La Roche Ltd21
进行中（未招募）
1 期
Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophyMedDRA version: 20.1Level: PTClassification code 10052655Term: Duchenne muscular dystrophy gene carrierSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2022-000691-19-DEF. Hoffmann-La Roche Ltd21
暂停
2 期
Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophyDuchenne Muscular Dystrophy2023-509901-57-00F. Hoffmann-La Roche AG15
进行中（未招募）
1 期
A study to evaluate the effect of itraconazole and carbamazepine on the processing of fenebrutinib by the body in healthy participantsHealthy volunteersISRCTN12005942Genentech32